FDA Cracks Down on Pregnancy Drug Safety Data

The US Food and Drug Administration (FDA) has finalized industry guidance to enhance the collection of post-marketing safety data for drugs and biologics concerning pregnant individuals. This framework is designed to help drugmakers develop more informative labels by detailing how to best design pregnancy registries and conduct various post-approval studies.

Recommendations emphasize flexible, multi-pronged recruitment and retention strategies for studies, encouraging early enrollment and sustained patient participation. The FDA advises engaging with patient advocacy groups and medical societies to raise awareness. These measures aim to address the significant knowledge gaps that persist due to the historical exclusion of pregnant women from clinical trials.

Furthermore, the guidance details statistical approaches for safety studies, advocating for prespecified analyses for each pregnancy outcome, such as miscarriage, stillbirth, termination, and live birth. It also suggests consulting with pediatric, statistical, genetics, and obstetrics experts, along with adhering to best practices for observational research and real-world data collection.

This initiative by the FDA aims to equip healthcare providers with more reliable information, thereby improving their ability to counsel pregnant patients and make informed treatment decisions. The framework is being introduced amidst reports of potential changes in FDA leadership.